Tepoxalin (BioDeep_00000012244)

 

Secondary id: BioDeep_00001868536

human metabolite blood metabolite


代谢物信息卡片


3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methylpropanamide

化学式: C20H20ClN3O3 (385.11931200000004)
中文名称: 特波沙林
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CN(C(=O)CCC1=NN(C(=C1)C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)OC)O
InChI: InChI=1S/C20H20ClN3O3/c1-23(26)20(25)12-7-16-13-19(14-3-5-15(21)6-4-14)24(22-16)17-8-10-18(27-2)11-9-17/h3-6,8-11,13,26H,7,12H2,1-2H3

描述信息

C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents
D002491 - Central Nervous System Agents > D000700 - Analgesics
D000893 - Anti-Inflammatory Agents
D018501 - Antirheumatic Agents
Tepoxalin is a dual inhibitor of COX and 5-lipoxygenase (5-LO) with potent anti-inflammatory activity and a favorable gastrointestinal profile[1].

同义名列表

12 个代谢物同义名

3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methylpropanamide; 5-(4-Chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-1H-pyrazole-3-propanamide; 5-(p-Chlorophenyl)-1-(p-methoxyphenyl)-N-methylpyrazole-3-propionohydroxamic acid; 5-(p-Chlorophenyl)-1-(p-methoxyphenyl)-N-methylpyrazole-3-propionohydroxamate; Tepoxaliume; Tepoxalina; Tepoxaline; TEPOXALIN; RWJ 20485; ORF 20485; ORF-20485; Zubrin



数据库引用编号

14 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Carlize Lopes, Adriano B Carregaro, Gabrielle C Freitas, Vanessa S Padilha, Rafael Lukarsewski, Francine C Paim, Sônia TdA Lopes. Effect of tepoxalin on renal function and hepatic enzymes in dogs exposed to hypotension with isoflurane. Veterinary anaesthesia and analgesia. 2014 Sep; 41(5):459-67. doi: 10.1111/vaa.12129. [PMID: 24961730]
  • Amy L Lomas, Shane D Lyon, Michael W Sanderson, Gregory F Grauer. Acute and chronic effects of tepoxalin on kidney function in dogs with chronic kidney disease and osteoarthritis. American journal of veterinary research. 2013 Jun; 74(6):939-44. doi: 10.2460/ajvr.74.6.939. [PMID: 23718664]
  • Tokiko Kushiro-Banker, Robert D Keegan, Michelle A Decourcey, Tamara L Grubb, Stephen A Greene, Robert Armstrong. Effects of tepoxalin and medetomidine on glomerular filtration rate in dogs. The Journal of veterinary medical science. 2013 Jan; 75(1):69-74. doi: 10.1292/jvms.12-0062. [PMID: 22986275]
  • R C Goupil, J J Bushey, J Peters-Kennedy, J J Wakshlag. Prevalence of 5-lipoxygenase expression in canine osteosarcoma and the effects of a dual 5-lipoxygenase/cyclooxygenase inhibitor on osteosarcoma cells in vitro and in vivo. Veterinary pathology. 2012 Sep; 49(5):802-10. doi: 10.1177/0300985811432350. [PMID: 22287649]
  • Mario Giorgi, Barbara Cuniberti, Guisheng Ye, Raffaella Barbero, Micaela Sgorbini, Cristina Vercelli, Michele Corazza, Giovanni Re. Oral administration of tepoxalin in the horse: a PK/PD study. Veterinary journal (London, England : 1997). 2011 Oct; 190(1):143-9. doi: 10.1016/j.tvjl.2010.09.013. [PMID: 21036634]
  • Joseph J Wakshlag, Jeanine Peters-Kennedy, Jennifer J Bushey, John P Loftus. 5-lipoxygenase expression and tepoxalin-induced cell death in squamous cell carcinomas in cats. American journal of veterinary research. 2011 Oct; 72(10):1369-77. doi: 10.2460/ajvr.72.10.1369. [PMID: 21962280]
  • Mario Giorgi, Grazia Mengozzi, Andrea Raffaelli, Alessandro Saba. Characterization of in vivo plasma metabolites of tepoxalin in horses using LC-MS-MS. Journal of pharmaceutical and biomedical analysis. 2011 Aug; 56(1):45-53. doi: 10.1016/j.jpba.2011.03.028. [PMID: 21497474]
  • S de Boever, E A Neirinckx, E Meyer, S de Baere, R Beyaert, P de Backer, S Croubels. Pharmacodynamics of tepoxalin, sodium-salicylate and ketoprofen in an intravenous lipopolysaccharide inflammation model in broiler chickens. Journal of veterinary pharmacology and therapeutics. 2010 Dec; 33(6):564-72. doi: 10.1111/j.1365-2885.2010.01184.x. [PMID: 21062309]
  • Laura A Goodman, Bryan T Torres, Lisa R Reynolds, Steven C Budsberg. Effects of firocoxib, meloxicam, and tepoxalin administration on eicosanoid production in target tissues of healthy cats. American journal of veterinary research. 2010 Sep; 71(9):1067-73. doi: 10.2460/ajvr.71.9.1067. [PMID: 20807147]
  • L Goodman, B Torres, J Punke, L Reynolds, A Speas, A Ellis, S Budsberg. Effects of firocoxib and tepoxalin on healing in a canine gastric mucosal injury model. Journal of veterinary internal medicine. 2009 Jan; 23(1):56-62. doi: 10.1111/j.1939-1676.2008.0226.x. [PMID: 19175721]
  • John P Punke, Abbie L Speas, Lisa R Reynolds, Steven C Budsberg. Effects of firocoxib, meloxicam, and tepoxalin on prostanoid and leukotriene production by duodenal mucosa and other tissues of osteoarthritic dogs. American journal of veterinary research. 2008 Sep; 69(9):1203-9. doi: 10.2460/ajvr.69.9.1203. [PMID: 18764695]
  • C G Pollock, J W Carpenter, D E Koch, R P Hunter. Single and multiple-dose pharmacokinetics of tepoxalin and its active metabolite after oral administration to rabbits (Oryctolagus cuniculus). Journal of veterinary pharmacology and therapeutics. 2008 Apr; 31(2):171-4. doi: 10.1111/j.1365-2885.2007.00937.x. [PMID: 18307510]
  • M Fusellier, J-C Desfontis, S Madec, F Gautier, L Marescaux, M Debailleul, M Gogny. Effect of tepoxalin on renal function in healthy dogs receiving an angiotensin-converting enzyme inhibitor. Journal of veterinary pharmacology and therapeutics. 2005 Dec; 28(6):581-6. doi: 10.1111/j.1365-2885.2005.00685.x. [PMID: 16343292]
  • L M Homer, C R Clarke, A J Weingarten. Effect of dietary fat on oral bioavailability of tepoxalin in dogs. Journal of veterinary pharmacology and therapeutics. 2005 Jun; 28(3):287-91. doi: 10.1111/j.1365-2885.2005.00644.x. [PMID: 15953202]
  • Patricia A Kay-Mugford, Kurt A Grimm, Allan J Weingarten, Philippe Brianceau, Patrick Lockwood, Jean Cao. Effect of preoperative administration of tepoxalin on hemostasis and hepatic and renal function in dogs. Veterinary therapeutics : research in applied veterinary medicine. 2004; 5(2):120-7. doi: NULL. [PMID: 15468009]
  • R E Willburger, R H Wittenberg, K Schmidt, K S Kleemeyer, B A Peskar. Antiinflammatory effect of tepoxalin: blood and synovial tissue studied in patients with knee arthrosis. Acta orthopaedica Scandinavica. 1998 Jun; 69(3):295-300. doi: 10.3109/17453679809000934. [PMID: 9703407]
  • T Kirchner, B Aparicio, D C Argentieri, C Y Lau, D M Ritchie. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins, leukotrienes, and essential fatty acids. 1997 Jun; 56(6):417-23. doi: 10.1016/s0952-3278(97)90593-7. [PMID: 9223651]
  • E V Knight, J P Kimball, C M Keenan, I L Smith, F A Wong, D S Barrett, A M Dempster, W G Lieuallen, D Panigrahi, W J Powers, R J Szot. Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs. Fundamental and applied toxicology : official journal of the Society of Toxicology. 1996 Sep; 33(1):38-48. doi: 10.1006/faat.1996.0141. [PMID: 8812216]
  • S A Waldman, C Vitow, B Osborne, L Gillen, D C Argentieri, F A Wong, I L Smith, A T Chow, J Misiti, T D Bjornsson. Pharmacokinetics and pharmacodynamics of tepoxalin after single oral dose administration to healthy volunteers. Journal of clinical pharmacology. 1996 May; 36(5):462-8. doi: 10.1002/j.1552-4604.1996.tb05033.x. [PMID: 8739025]
  • M Depré, A Van Hecken, R Verbesselt, G A Verpooten, J Arnout, F Brunner, A Jurgens, V Pousset, A Chow, C Baldauf, J Vermylen, M De Broe, P J De Schepper. Biochemical activity, pharmacokinetics and tolerability of tepoxalin, a cyclooxygenase/5-lipoxygenase inhibitor, in man. International journal of clinical pharmacology research. 1996; 16(1):1-8. doi: NULL. [PMID: 9001924]
  • K D Rainsford, C Ying, F Smith. Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: comparison with interleukin-1-synthesis inhibitors. The Journal of pharmacy and pharmacology. 1996 Jan; 48(1):46-52. doi: 10.1111/j.2042-7158.1996.tb05875.x. [PMID: 8722494]
  • J H Musser, A F Kreft. 5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors. Journal of medicinal chemistry. 1992 Jul; 35(14):2501-24. doi: 10.1021/jm00092a001. [PMID: 1635053]